Related Experiment Video
Updated: Jun 22, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
D-ribose, a metabolic substrate for congestive heart failure
Susan Wagner1, James Herrick, Linda M Shecterle
1Saddleback Memorial Hospital, Laguna, CA, USA.
Progress in Cardiovascular Nursing
|June 16, 2009
Summary
Congestive heart failure patients may benefit from D-ribose, a natural sugar that replenishes cellular energy. This approach targets the energy-deficient state in heart failure, potentially improving patient outcomes.
Area of Science:
- Cardiology
- Biochemistry
- Metabolic Research
Background:
- Congestive heart failure (CHF) incidence is rising globally, overwhelming healthcare systems.
- Current CHF therapies primarily focus on clinical management, but disease progression persists in most patients.
- The failing heart is understood to be in an energy-deficient state, necessitating novel therapeutic strategies.
Purpose of the Study:
- To investigate the potential of D-ribose as a therapeutic agent for congestive heart failure.
- To explore D-ribose's role in replenishing adenosine triphosphate (ATP) levels in cardiac cells.
- To assess D-ribose's efficacy in improving diastolic dysfunction and the clinical status of CHF patients.
Main Methods:
- Literature review on D-ribose's biochemical properties and effects on myocardial ischemia.
- Analysis of studies demonstrating D-ribose's impact on ATP levels and diastolic function.
- Evaluation of clinical data showing improvements in CHF patients treated with D-ribose.
Main Results:
- D-ribose, a naturally occurring pentose carbohydrate, is a key component of adenosine triphosphate (ATP).
- D-ribose has shown the ability to restore ATP levels in energy-depleted tissues.
- Studies indicate D-ribose improves diastolic dysfunction following myocardial ischemia, leading to better clinical outcomes in CHF patients.
Conclusions:
- D-ribose may serve as a crucial metabolic substrate to address the energy deficit in heart failure.
- Supplementation with D-ribose presents a promising therapeutic avenue for stabilizing CHF and potentially reversing disease progression.
- Further research into D-ribose for heart failure management is warranted to optimize its clinical application.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...